根据一份提交给美国证券交易委员会(SEC)的文件显示,截至2025年12月31日,制药巨头礼来公司已将价值15亿美元的待上市产品库存进行资本化处理。据悉,这笔巨额库存资本化主要与其候选药物Orforglipron相关。
根据一份提交给美国证券交易委员会(SEC)的文件显示,截至2025年12月31日,制药巨头礼来公司已将价值15亿美元的待上市产品库存进行资本化处理。据悉,这笔巨额库存资本化主要与其候选药物Orforglipron相关。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.